US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

COYA THERAPEUTICS INC

6.37

+0.09001.43%

Post-market: 6.670.3000+4.71%17:25 EDT

Volume:37.68K

Turnover:240.48K

Market Cap:106.54M

PE:-6.52

High:6.55

Open:6.34

Low:6.26

Close:6.28

Loading ...

Overview Company News Filings

Coya Therapeutics Inc Files for Resale of up to 1.4 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics: Expects in Q1/Q2 2025 Coya 301/Glp-1 Combination Data Submission for Publication and Additional Intellectual Property Filings

THOMSON REUTERS

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

Coya Therapeutics New CEO Arun Swaminathan Takes Helm

MT Newswires Live

Coya Therapeutics Announces Arun Swaminathan, Ph.d. Assumes New Role as Chief Executive Officer

THOMSON REUTERS

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Is Maintained at Buy by Chardan Capital

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results

MT Newswires Live

Coya Therapeutics Shares Reverse Course; Last Down 23.6%

THOMSON REUTERS

Coya Therapeutics Shares up 13.7% on Positive Immune Response, Safety in Mid-Stage Alzheimer's Drug Trial

THOMSON REUTERS

Coya Therapeutics Shares up 7.8% Premarket on Positive Immune Response, Safety in Mid-Stage Alzheimer's Drug Trial

THOMSON REUTERS

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics: Study Met Primary and Secondary Endpoints

THOMSON REUTERS

Coya Therapeutics: Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (Ld Il-2) in Alzheimer’s Disease

THOMSON REUTERS

Coya Therapeutics: Exploratory Endpoints Showed Cognitive Stabilization on Treatment VS Cognitive Declines on Placebo for Ld Il-2 Dosing Every 4-Week

THOMSON REUTERS

Coya Therapeutics Announces Conference Call to Report Results From an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients With Mild to Moderate Alzheimer’s Disease

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/COYA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COYA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","market":"US","secType":"STK","nameCN":"COYA THERAPEUTICS INC","latestPrice":6.37,"timestamp":1746216000000,"preClose":6.28,"halted":0,"volume":37675,"hourTrading":{"tag":"盘后","latestPrice":6.67,"preClose":6.37,"latestTime":"17:25 EDT","volume":150,"amount":998.34,"timestamp":1746221140335},"delay":0,"floatShares":12564296,"shares":16724998,"eps":-0.976498,"marketStatus":"Market Closed","change":0.09,"latestTime":"05-02 16:00:00 EDT","open":6.34,"high":6.5518,"low":6.26,"amount":240478.7715,"amplitude":0.046465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976498,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1672290000000,"exchange":"NASDAQ","adjPreClose":6.28,"preHourTrading":{"tag":"盘前","latestPrice":6.59,"preClose":6.28,"latestTime":"09:29 EDT","volume":111,"amount":738.460023,"timestamp":1746192546223},"postHourTrading":{"tag":"盘后","latestPrice":6.67,"preClose":6.37,"latestTime":"17:25 EDT","volume":150,"amount":998.34,"timestamp":1746221140335},"volumeRatio":0.981923},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","floatShares":12564296,"roa":"-25.15%","roe":"-39.57%","lyrEps":-0.976498,"volumeRatio":0.981923,"shares":16724998,"dividePrice":0,"high":6.5518,"amplitude":0.046465,"preClose":6.28,"low":6.26,"week52Low":4.65,"pbRate":"2.69","psRate":"29.98","week52High":10.24,"institutionHeld":0,"latestPrice":6.37,"eps":-0.976498,"divideRate":0,"volume":37675,"delay":0,"ttmEps":-0.976498,"open":6.34,"prevYearClose":5.73,"prevWeekClose":6.18,"prevMonthClose":6.59,"prevQuarterClose":6.47,"fiveDayClose":6.18,"twentyDayClose":6.1,"sixtyDayClose":6.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COYA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2485174326","title":"Coya Therapeutics Inc Files for Resale of up to 1.4 Mln Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2485174326","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485174326?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:17","pubTimestamp":1732141026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR1BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2484427899","title":"Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2484427899","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484427899?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:15","pubTimestamp":1732022100,"startTime":"0","endTime":"0","summary":"HOUSTON, November 19, 2024----Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the \"innovation and get-it-done\" culture in Coya’s DNA. We have made tremendous strides in 2024, repeatedly executing on our promises. As I look to 2025, I am confident that our nimble and highly experienced team will continue to exceed expectations.FTD  Program: We expect to see topline results in 2H 2025 from the investigator-initiated, open-label study of Low Dose IL-2  + CTLA4-Ig in FTD. Study endpoints will measure safety, peripheral and central inflammation, FTD progression, and pharmacodynamic effects on Treg cell population","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-ceo-dr-arun-131500544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COYA","LENZ","BK4139"],"gpt_icon":1},{"id":"2481360602","title":"Coya Therapeutics: Expects in Q1/Q2 2025 Coya 301/Glp-1 Combination Data Submission for Publication and Additional Intellectual Property Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2481360602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481360602?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA7RHK3T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2481460614","title":"Press Release: Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481460614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481460614?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell  function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024.-- Announced positive results from an investigator initiated double-blind. study of low-dose interleukin-2  in patients with mild to. moderate Alzheimer's Disease  at the Clinical Trials on Alzheimer's. -- Filed patents for COYA 301 in combination with Glucagon-Like Peptide-1. -- Promoted Arun Swaminathan, Ph.D. to Chief Executive Officer, effective. November 1, 2024, while Howard Berman has transitioned from CEO to. -- Announced anti-inflammatory effects of COYA 302 in the brain from a. -- Aligned with FDA on the non-clinical data needed to support the planned. randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302. -- A Phase 1 investigator-initiated trial  combining LD IL-2 + CTLA4-Ig. investigator-initiated trial  study in pati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","COYA","CSF","LU1169589451.USD","LENZ","BK4139","BK4023"],"gpt_icon":0},{"id":"2481762786","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481762786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481762786?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:00","pubTimestamp":1730890800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASC","ERAS","ASH","ACT","CXDO","BWMN","AMD","NVDA","QCOM","ET","CLDX","EHAB","COHR","BROS","BIRD","BAK","BATRK","BHVN","AUDC","AAPL","ALB","ECPG","INTC","ABUS","PLUS","ALNT","BATRA","CHRD","EBS","OBDC","ACLS","ATS","ALTG","AEVA","TSM","EVO","APP","BKD","COYA","CYTK","ASML","AMPY","BIP","LAW","AEE","EFC","AADI","ASPN","MU","DK","EHTH","CHT","CERT","CXT","EVTC","MSFT","AMZN","CLBT","CURI"],"gpt_icon":1},{"id":"2480000718","title":"Coya Therapeutics New CEO Arun Swaminathan Takes Helm","url":"https://stock-news.laohu8.com/highlight/detail?id=2480000718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480000718?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:40","pubTimestamp":1730464812,"startTime":"0","endTime":"0","summary":"Coya Therapeutics (COYA) said Friday that Arun Swaminathan has begun his term as the company's chief executive officer.The company said in August that Swaminathan, who was most recently Coya's chief business officer, succeeds Howard Berman, who will continue as executive chair.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","COYA"],"gpt_icon":0},{"id":"2480027470","title":"Coya Therapeutics Announces Arun Swaminathan, Ph.d. Assumes New Role as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480027470","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480027470?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:15","pubTimestamp":1730463300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nTUA1CGGZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2480100717","title":"Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480100717","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480100717?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:15","pubTimestamp":1730463300,"startTime":"0","endTime":"0","summary":"Company underscores potential benefits of low-dose interleukin-2 in Investigator-Initiated Phase 2 Alzheimer’s disease trial as presented at the recent CTAD Conference. Dr. Swaminathan commented, \"I would like to again thank our board of directors and Executive Chairman Howard Berman for the opportunity to lead Coya. Our pipeline targets severe neurodegenerative diseases facing millions of people across the globe, such as Amyotrophic Lateral Sclerosis , Alzheimer’s disease, Frontotemporal Dementia, and Parkinson’s disease. We believe our combination therapeutic approach targeting neuroinflammation can unlock a new paradigm in neurodegenerative treatment.Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans. In more than 90% of people with Alzheimer’s, symptoms do not appea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-arun-swaminathan-121500783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","LU1169590202.USD","COYA","LU1169589451.USD","LENZ","BK4139","BK4023"],"gpt_icon":1},{"id":"2479120746","title":"Coya Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2479120746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479120746?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:05","pubTimestamp":1730293500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 09:05 ET (13:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","COYA"],"gpt_icon":0},{"id":"2479258143","title":"Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2479258143","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479258143?lang=en_us&edition=fundamental","pubTime":"2024-10-30 02:36","pubTimestamp":1730227012,"startTime":"0","endTime":"0","summary":"On Tuesday, Coya Therapeutics, Inc.  released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease.The data was shared at the Clinical Trials on Alzheimer’s Disease Conference .The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients with Alzheimer’s.Also Read: EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases. LD IL-2 showed targeted biological activity. Additionally, the q4wks regimen led to significant improvements  in cerebrospinal fluid  soluble Aβ42 levels, an indicator of amyloid pathology.However, the company said that the q2wks group, representing the higher total dose cohort, did not exhibit benefits in exploratory endpoints.The company will likely advance LD IL-2 q4wks.This cognitive effect was not observed in the LD IL","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9b7J0yyZ459Dk3tzGCqVRA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/e0b14ce53415bbfc1505fe19089ea725","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9b7J0yyZ459Dk3tzGCqVRA--~B/aD01NzQ7dz0xMDIwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/e0b14ce53415bbfc1505fe19089ea725"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-high-dose-interleukin-183652461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","LENZ","COYA","CSF","BK4139"],"gpt_icon":0},{"id":"2479223553","title":"Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2479223553","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479223553?lang=en_us&edition=fundamental","pubTime":"2024-10-30 00:20","pubTimestamp":1730218846,"startTime":"0","endTime":"0","summary":"Coya Therapeutics  shares fell nearly 23% in recent Tuesday trading after the company reported results from its phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.The placebo-controlled study evaluated two dosing regimens of subcutaneous low-dose interleukin-2, or IL-2. The trial met its primary and secondary goals for safety and enhancing regulatory T cell, or Treg, populations, respectively, the company said.The higher total dose group, however, \"did not exhibit benefits in exploratory endpoints, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on cerebrospinal fluid biomarkers and cognitive outcomes,\" the company said.Exploratory endpoints of the study examined changes in cerebrospinal fluid, Alzheimer's Disease-related biomarkers, and cognitive status, the company added.Price: 7.87, Change: -2.33, Percent Change: -22.82","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","COYA"],"gpt_icon":0},{"id":"2479854012","title":"Coya Therapeutics Shares Reverse Course; Last Down 23.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479854012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479854012?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:04","pubTimestamp":1730210674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M519J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2479199400","title":"Coya Therapeutics Shares up 13.7% on Positive Immune Response, Safety in Mid-Stage Alzheimer's Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2479199400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479199400?lang=en_us&edition=fundamental","pubTime":"2024-10-29 21:31","pubTimestamp":1730208666,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M519A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2479403519","title":"Coya Therapeutics Shares up 7.8% Premarket on Positive Immune Response, Safety in Mid-Stage Alzheimer's Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2479403519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479403519?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:35","pubTimestamp":1730201712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M50OQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2479474317","title":"Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479474317","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479474317?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":"Study met Primary and Secondary Endpoints for Safety and Regulatory T cell  Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement. Exploratory Endpoints demonstrated cognitive stabilization on treatment vs. cognitive declines on placebo for LD IL-2 dosing every 4 weeks , which was associated with significant improvement in cerebrospinal fluid  soluble Aβ42 levels and stabilized CSF Neurofilament Light Chain . Study supports and increases confidence in Treg modulation strategies in neurodegenerative conditions and in advancing LD IL-2 q4wks and LD IL-2 q4wks combination strategies  in AD and other related diseases. Of the 38 total participants, 22 were randomized in a 1:1 ratio to receive either 5 days of LD IL-2   or placebo ever","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-positive-results-103000665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","LU1169590202.USD","PD","BK4023","MFI","CSF","COYA","BK4139","LD","BK4127","LU1169589451.USD"],"gpt_icon":1},{"id":"2479471623","title":"Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2479471623","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479471623?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":"Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trialBy Bhanvi Satija and Christy SanthoshOct 29 (Reuters) - Coya Therapeutics COYA.O said on Tuesday its exper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nL4N3M41EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0471298694.HKD","LU0094547139.USD","BK4581","LU0114720955.EUR","IE00BK4W5L77.USD","IE00B894F039.SGD","LU0198837287.USD","LU0238689110.USD","LU0823416689.USD","IE00BFTCPJ56.SGD","LU0097036916.USD","IE0004445239.USD","LU0820561818.USD","IE00B19Z9Z06.USD","GB00BDT5M118.USD","BK4139","LU0882574139.USD","LU0203202063.USD","LU0820561909.HKD","IE0002141913.USD","LU0122379950.USD","LU0466842654.USD","LU0640476718.USD","LU0689472784.USD","COYA","LU0320765059.SGD","LLY","IE00BJJMRZ35.SGD","LU0079474960.USD","LU0882574055.USD","BK4533","LU0234570918.USD","LU1057294990.SGD","IE00B19Z9P08.USD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","BK4532","LU1093756168.USD","BIIB","LU0061475181.USD","LU0109391861.USD","LU1035775433.USD","LU0385154629.USD","LU0106261372.USD","LU0456855351.SGD","LU0256863811.USD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4588"],"gpt_icon":1},{"id":"2479471330","title":"Coya Therapeutics: Study Met Primary and Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2479471330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479471330?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nP8N3JN0FE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2479471328","title":"Coya Therapeutics: Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (Ld Il-2) in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2479471328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479471328?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nP8N3JN0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2479471320","title":"Coya Therapeutics: Exploratory Endpoints Showed Cognitive Stabilization on Treatment VS Cognitive Declines on Placebo for Ld Il-2 Dosing Every 4-Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2479471320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479471320?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nP8N3JN0FE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2478101079","title":"Coya Therapeutics Announces Conference Call to Report Results From an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients With Mild to Moderate Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2478101079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478101079?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nTUA6JHRZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COYA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COYA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COYA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1742875200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COYA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COYA","date":"2025-05-01","current":-7.406714,"percent":0.503571,"low":-18.170827,"twenty":-10.328659,"median":-7.47415,"eighty":-3.648656,"high":-2.532969,"avg":-7.448093,"sd":3.874837,"marketCap":110217736},"quantilePoints":[{"date":"2022-12-30","current":-4.259584,"twenty":-5.088378,"median":-4.673981,"eighty":-4.199135,"marketCap":45862003},{"date":"2023-01-06","current":-4.198451,"twenty":-4.75686,"median":-4.211892,"eighty":-4.164199,"marketCap":45203803},{"date":"2023-01-13","current":-4.315322,"twenty":-4.421315,"median":-4.259584,"eighty":-4.180381,"marketCap":46462126},{"date":"2023-01-20","current":-4.288262,"twenty":-4.396143,"median":-4.253021,"eighty":-4.180381,"marketCap":46170776},{"date":"2023-01-27","current":-4.181765,"twenty":-4.394298,"median":-4.256303,"eighty":-4.180658,"marketCap":45024142},{"date":"2023-02-03","current":-3.675163,"twenty":-4.351211,"median":-4.234322,"eighty":-4.117451,"marketCap":39569675},{"date":"2023-02-10","current":-3.877804,"twenty":-4.30991,"median":-4.190108,"eighty":-3.84096,"marketCap":41751462},{"date":"2023-02-17","current":-3.850171,"twenty":-4.288262,"median":-4.180381,"eighty":-3.855698,"marketCap":41453946},{"date":"2023-02-24","current":-3.684374,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":39668848},{"date":"2023-03-03","current":-4.089655,"twenty":-4.270282,"median":-4.071233,"eighty":-3.770128,"marketCap":44032421},{"date":"2023-03-10","current":-4.23703,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":45619175},{"date":"2023-03-17","current":-3.905437,"twenty":-4.29377,"median":-4.180381,"eighty":-3.822538,"marketCap":42048978},{"date":"2023-03-24","current":-3.73964,"twenty":-4.288262,"median":-4.108461,"eighty":-3.73964,"marketCap":40263880},{"date":"2023-03-31","current":-3.218192,"twenty":-4.288262,"median":-4.048207,"eighty":-3.707402,"marketCap":39406041},{"date":"2023-04-06","current":-3.099387,"twenty":-4.273878,"median":-3.979124,"eighty":-3.684448,"marketCap":37951295},{"date":"2023-04-14","current":-3.233436,"twenty":-4.261724,"median":-3.905437,"eighty":-3.63832,"marketCap":39592701},{"date":"2023-04-21","current":-3.534032,"twenty":-4.256278,"median":-3.877804,"eighty":-3.512909,"marketCap":43273430},{"date":"2023-04-28","current":-3.753386,"twenty":-4.253993,"median":-3.850523,"eighty":-3.541339,"marketCap":45959367},{"date":"2023-05-05","current":-4.053981,"twenty":-4.248953,"median":-3.850876,"eighty":-3.590423,"marketCap":49640095},{"date":"2023-05-12","current":-3.858435,"twenty":-4.25448,"median":-3.877804,"eighty":-3.627267,"marketCap":51231762},{"date":"2023-05-19","current":-4.210564,"twenty":-4.257931,"median":-3.905437,"eighty":-3.63832,"marketCap":55907282},{"date":"2023-05-26","current":-3.109224,"twenty":-4.25448,"median":-3.877804,"eighty":-3.560217,"marketCap":41283847},{"date":"2023-06-02","current":-3.431385,"twenty":-4.251665,"median":-3.850876,"eighty":-3.429011,"marketCap":45561450},{"date":"2023-06-09","current":-3.611196,"twenty":-4.244399,"median":-3.84096,"eighty":-3.421013,"marketCap":47948950},{"date":"2023-06-16","current":-3.618688,"twenty":-4.23703,"median":-3.850171,"eighty":-3.424798,"marketCap":48048429},{"date":"2023-06-23","current":-3.566243,"twenty":-4.23703,"median":-3.830566,"eighty":-3.428417,"marketCap":47352075},{"date":"2023-06-30","current":-3.146685,"twenty":-4.23703,"median":-3.818461,"eighty":-3.418016,"marketCap":41781243},{"date":"2023-07-07","current":-3.071764,"twenty":-4.235405,"median":-3.785695,"eighty":-3.362458,"marketCap":40786451},{"date":"2023-07-14","current":-3.041795,"twenty":-4.228928,"median":-3.76675,"eighty":-3.288681,"marketCap":40388534},{"date":"2023-07-21","current":-2.981859,"twenty":-4.224887,"median":-3.746054,"eighty":-3.233436,"marketCap":39592701},{"date":"2023-07-28","current":-3.019319,"twenty":-4.216174,"median":-3.721218,"eighty":-3.218192,"marketCap":40090097},{"date":"2023-08-04","current":-2.876969,"twenty":-4.203296,"median":-3.712007,"eighty":-3.16841,"marketCap":38199993},{"date":"2023-08-11","current":-2.839996,"twenty":-4.188439,"median":-3.693585,"eighty":-3.145639,"marketCap":36807285},{"date":"2023-08-18","current":-2.54832,"twenty":-4.180935,"median":-3.684466,"eighty":-3.105289,"marketCap":33027077},{"date":"2023-08-25","current":-2.709509,"twenty":-4.180381,"median":-3.675163,"eighty":-3.078507,"marketCap":35116139},{"date":"2023-09-01","current":-2.709509,"twenty":-4.180381,"median":-3.63832,"eighty":-3.046291,"marketCap":35116139},{"date":"2023-09-08","current":-3.691995,"twenty":-4.169593,"median":-3.63832,"eighty":-3.044792,"marketCap":47849471},{"date":"2023-09-15","current":-3.546157,"twenty":-4.135431,"median":-3.63832,"eighty":-3.058278,"marketCap":45959367},{"date":"2023-09-21","current":-3.031887,"twenty":-4.1047,"median":-3.619293,"eighty":-3.053783,"marketCap":39294264},{"date":"2023-09-29","current":-3.162374,"twenty":-4.08252,"median":-3.599887,"eighty":-3.071764,"marketCap":40985409},{"date":"2023-10-06","current":-2.594374,"twenty":-4.053747,"median":-3.556227,"eighty":-3.033869,"marketCap":33623952},{"date":"2023-10-13","current":-3.745724,"twenty":-4.05097,"median":-3.54621,"eighty":-3.041795,"marketCap":48545825},{"date":"2023-10-20","current":-3.937616,"twenty":-4.036232,"median":-3.575206,"eighty":-3.043294,"marketCap":51032803},{"date":"2023-10-27","current":-3.645941,"twenty":-4.021495,"median":-3.590557,"eighty":-3.046291,"marketCap":47252596},{"date":"2023-11-03","current":-3.684319,"twenty":-3.985193,"median":-3.599887,"eighty":-3.062774,"marketCap":47749992},{"date":"2023-11-10","current":-3.870934,"twenty":-4.021495,"median":-3.619293,"eighty":-3.071764,"marketCap":47850465},{"date":"2023-11-17","current":-4.057134,"twenty":-4.055242,"median":-3.63832,"eighty":-3.071764,"marketCap":50152180},{"date":"2023-11-24","current":-4.259991,"twenty":-4.064747,"median":-3.645941,"eighty":-3.07577,"marketCap":52659789},{"date":"2023-12-01","current":-4.324905,"twenty":-4.105159,"median":-3.675163,"eighty":-3.082268,"marketCap":53462223},{"date":"2023-12-08","current":-5.631302,"twenty":-4.180381,"median":-3.684374,"eighty":-3.084048,"marketCap":69611225},{"date":"2023-12-15","current":-7.875233,"twenty":-4.205719,"median":-3.689056,"eighty":-3.088687,"marketCap":97349529},{"date":"2023-12-22","current":-7.933482,"twenty":-4.235947,"median":-3.693585,"eighty":-3.093672,"marketCap":98069570},{"date":"2023-12-29","current":-8.842163,"twenty":-4.23703,"median":-3.709704,"eighty":-3.09424,"marketCap":109302208},{"date":"2024-01-05","current":-7.793685,"twenty":-4.253993,"median":-3.715021,"eighty":-3.09424,"marketCap":96341472},{"date":"2024-01-12","current":-7.877698,"twenty":-4.259991,"median":-3.721218,"eighty":-3.097328,"marketCap":97379997},{"date":"2024-01-19","current":-6.724011,"twenty":-4.272114,"median":-3.742682,"eighty":-3.100019,"marketCap":83118725},{"date":"2024-01-26","current":-6.99204,"twenty":-4.300291,"median":-3.753386,"eighty":-3.10427,"marketCap":86431950},{"date":"2024-02-02","current":-7.213454,"twenty":-4.321125,"median":-3.76675,"eighty":-3.109224,"marketCap":89168961},{"date":"2024-02-09","current":-7.935965,"twenty":-4.359055,"median":-3.785695,"eighty":-3.121212,"marketCap":98100263},{"date":"2024-02-16","current":-8.91485,"twenty":-4.404211,"median":-3.812795,"eighty":-3.139255,"marketCap":110200736},{"date":"2024-02-23","current":-10.04523,"twenty":-4.438913,"median":-3.822509,"eighty":-3.140292,"marketCap":124173901},{"date":"2024-03-01","current":-10.476406,"twenty":-5.628056,"median":-3.830566,"eighty":-3.144593,"marketCap":129503871},{"date":"2024-03-08","current":-10.441446,"twenty":-5.900696,"median":-3.837832,"eighty":-3.146685,"marketCap":129071712},{"date":"2024-03-15","current":-11.653399,"twenty":-6.72168,"median":-3.850171,"eighty":-3.146685,"marketCap":144053250},{"date":"2024-03-22","current":-18.042053,"twenty":-6.870845,"median":-3.854655,"eighty":-3.146752,"marketCap":144116957},{"date":"2024-03-28","current":-17.568699,"twenty":-6.99204,"median":-3.858435,"eighty":-3.147022,"marketCap":140335887},{"date":"2024-04-05","current":-16.744948,"twenty":-7.213454,"median":-3.877804,"eighty":-3.154698,"marketCap":133755895},{"date":"2024-04-12","current":-16.708387,"twenty":-7.481482,"median":-3.895399,"eighty":-3.162374,"marketCap":133463852},{"date":"2024-04-19","current":-15.428751,"twenty":-7.933482,"median":-3.905437,"eighty":-3.168361,"marketCap":123242331},{"date":"2024-04-26","current":-15.41047,"twenty":-7.947618,"median":-3.91531,"eighty":-3.168442,"marketCap":123096309},{"date":"2024-05-03","current":-16.050288,"twenty":-8.108228,"median":-3.925864,"eighty":-3.184145,"marketCap":128207070},{"date":"2024-05-10","current":-15.465312,"twenty":-8.157379,"median":-3.945867,"eighty":-3.193076,"marketCap":123534375},{"date":"2024-05-17","current":-12.046492,"twenty":-8.434421,"median":-4.006757,"eighty":-3.19913,"marketCap":124118462},{"date":"2024-05-24","current":-12.027546,"twenty":-8.842163,"median":-4.037702,"eighty":-3.208428,"marketCap":123923260},{"date":"2024-05-31","current":-11.153807,"twenty":-9.523158,"median":-4.053396,"eighty":-3.216239,"marketCap":114920875},{"date":"2024-06-07","current":-10.311731,"twenty":-10.30363,"median":-4.063993,"eighty":-3.218192,"marketCap":106244729},{"date":"2024-06-14","current":-11.493592,"twenty":-10.481448,"median":-4.089655,"eighty":-3.221544,"marketCap":118421776},{"date":"2024-06-21","current":-9.425336,"twenty":-10.483969,"median":-4.100207,"eighty":-3.22689,"marketCap":97111945},{"date":"2024-06-28","current":-8.996912,"twenty":-10.491151,"median":-4.108461,"eighty":-3.230001,"marketCap":92697765},{"date":"2024-07-05","current":-8.819633,"twenty":-10.481448,"median":-4.153411,"eighty":-3.232684,"marketCap":90871208},{"date":"2024-07-12","current":-10.592423,"twenty":-10.481448,"median":-4.180381,"eighty":-3.233436,"marketCap":109136778},{"date":"2024-07-15","current":-11.065167,"twenty":-10.491151,"median":-4.180381,"eighty":-3.233436,"marketCap":114007596},{"date":"2024-08-02","current":-9.957173,"twenty":-10.489011,"median":-4.181073,"eighty":-3.233436,"marketCap":102591615},{"date":"2024-08-09","current":-9.277604,"twenty":-10.476406,"median":-4.210564,"eighty":-3.233436,"marketCap":95589814},{"date":"2024-08-16","current":-7.550677,"twenty":-10.441446,"median":-4.229827,"eighty":-3.251575,"marketCap":76258753},{"date":"2024-08-23","current":-9.374293,"twenty":-10.311731,"median":-4.23703,"eighty":-3.274051,"marketCap":94676535},{"date":"2024-08-30","current":-8.852829,"twenty":-10.301605,"median":-4.249631,"eighty":-3.28015,"marketCap":89409963},{"date":"2024-09-06","current":-9.133154,"twenty":-10.286069,"median":-4.257518,"eighty":-3.290318,"marketCap":92241126},{"date":"2024-09-13","current":-8.982442,"twenty":-10.167203,"median":-4.259991,"eighty":-3.294066,"marketCap":90718995},{"date":"2024-09-20","current":-9.374293,"twenty":-10.063875,"median":-4.267746,"eighty":-3.325565,"marketCap":94676535},{"date":"2024-09-27","current":-9.46472,"twenty":-10.033878,"median":-4.288262,"eighty":-3.333863,"marketCap":95589814},{"date":"2024-10-04","current":-10.301173,"twenty":-10.081747,"median":-4.299205,"eighty":-3.345975,"marketCap":104037640},{"date":"2024-10-11","current":-10.45942,"twenty":-10.301259,"median":-4.315322,"eighty":-3.366953,"marketCap":105635877},{"date":"2024-10-18","current":-12.388535,"twenty":-10.462817,"median":-4.33302,"eighty":-3.382641,"marketCap":125119151},{"date":"2024-10-25","current":-14.93557,"twenty":-10.558363,"median":-4.357362,"eighty":-3.391203,"marketCap":150843162},{"date":"2024-10-31","current":-10.029891,"twenty":-10.623264,"median":-4.367898,"eighty":-3.402403,"marketCap":101297804},{"date":"2024-11-08","current":-10.271752,"twenty":-10.614867,"median":-4.40398,"eighty":-3.415739,"marketCap":109897843},{"date":"2024-11-15","current":-9.688453,"twenty":-10.599507,"median":-4.432103,"eighty":-3.422453,"marketCap":103657107},{"date":"2024-11-22","current":-9.494429,"twenty":-10.566878,"median":-5.088378,"eighty":-3.426607,"marketCap":101581241},{"date":"2024-11-29","current":-10.181526,"twenty":-10.529794,"median":-5.623188,"eighty":-3.429604,"marketCap":108932515},{"date":"2024-12-06","current":-9.338271,"twenty":-10.495432,"median":-5.858502,"eighty":-3.46435,"marketCap":99910497},{"date":"2024-12-13","current":-9.088417,"twenty":-10.483969,"median":-5.907187,"eighty":-3.516795,"marketCap":97237306},{"date":"2024-12-20","current":-8.057772,"twenty":-10.469612,"median":-6.712358,"eighty":-3.52129,"marketCap":86210395},{"date":"2024-12-27","current":-8.541863,"twenty":-10.455825,"median":-6.793932,"eighty":-3.523838,"marketCap":91389702},{"date":"2025-01-03","current":-8.916643,"twenty":-10.441446,"median":-6.852199,"eighty":-3.534032,"marketCap":95399488},{"date":"2025-01-10","current":-9.478813,"twenty":-10.430887,"median":-6.957079,"eighty":-3.543732,"marketCap":101414166},{"date":"2025-01-17","current":-8.744869,"twenty":-10.348577,"median":-6.99204,"eighty":-3.546199,"marketCap":93561669},{"date":"2025-01-24","current":-9.119649,"twenty":-10.325731,"median":-7.13188,"eighty":-3.555389,"marketCap":97571455},{"date":"2025-01-31","current":-9.150881,"twenty":-10.318171,"median":-7.256788,"eighty":-3.564349,"marketCap":97905604},{"date":"2025-02-07","current":-10.931086,"twenty":-10.318171,"median":-7.341641,"eighty":-3.568008,"marketCap":116952087},{"date":"2025-02-14","current":-10.681233,"twenty":-10.383279,"median":-7.550677,"eighty":-3.569184,"marketCap":114278896},{"date":"2025-02-21","current":-9.634972,"twenty":-10.398268,"median":-7.746602,"eighty":-3.574001,"marketCap":103084910},{"date":"2025-02-28","current":-10.509459,"twenty":-10.398268,"median":-7.876466,"eighty":-3.588691,"marketCap":112441077},{"date":"2025-03-07","current":-9.822362,"twenty":-10.45223,"median":-7.935965,"eighty":-3.604411,"marketCap":105089803},{"date":"2025-03-14","current":-10.119063,"twenty":-10.461335,"median":-7.947618,"eighty":-3.614193,"marketCap":108264217},{"date":"2025-03-21","current":-7.264209,"twenty":-10.461335,"median":-7.947618,"eighty":-3.619172,"marketCap":108097143},{"date":"2025-03-28","current":-7.743894,"twenty":-10.45223,"median":-7.935965,"eighty":-3.621104,"marketCap":115235236},{"date":"2025-04-04","current":-6.855987,"twenty":-10.436166,"median":-7.877698,"eighty":-3.629076,"marketCap":102022487},{"date":"2025-04-11","current":-5.540987,"twenty":-10.398268,"median":-7.770143,"eighty":-3.63832,"marketCap":82454240},{"date":"2025-04-17","current":-5.866927,"twenty":-10.3533,"median":-7.730177,"eighty":-3.639844,"marketCap":87304489},{"date":"2025-04-25","current":-7.339278,"twenty":-10.348372,"median":-7.507868,"eighty":-3.646484,"marketCap":109214236},{"date":"2025-05-01","current":-7.406714,"twenty":-10.328659,"median":-7.47415,"eighty":-3.648656,"marketCap":110217736}],"updateTime":1746247892566}}}